TransMedics Group (TMDX) Stock Forecast & Price Target

$80.11 +2.91 (+3.77%)

(As of 12:33 PM ET)

TransMedics Group - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 11 Analyst Ratings

Sell
0

Hold
1

Buy
10

Based on 11 Wall Street analysts who have issued ratings for TransMedics Group in the last 12 months, the stock has a consensus rating of "Buy." Out of the 11 analysts, 1 has given a hold rating, 9 have given a buy rating, and 1 has given a strong buy rating for TMDX.

Consensus Price Target

$131.80
64.52% Upside

According to the 11 analysts' twelve-month price targets for TransMedics Group, the average price target is $131.80. The highest price target for TMDX is $178.00, while the lowest price target for TMDX is $104.00. The average price target represents a forecasted upside of 64.52% from the current price of $80.11.

Get the Latest News and Ratings for TMDX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for TransMedics Group and its competitors.

TMDX Analyst Ratings Over Time

Type	Current Forecast 11/22/23 to 11/21/24	1 Month Ago 10/23/23 to 10/22/24	3 Months Ago 8/24/23 to 8/23/24	1 Year Ago 11/22/22 to 11/22/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	9 Buy rating(s)	9 Buy rating(s)	8 Buy rating(s)	7 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$131.80	$174.30	$171.44	$79.83
Forecasted Upside	64.52% Upside	41.78% Upside	-2.40% Downside	15.78% Upside
Consensus Rating	Buy	Buy	Moderate Buy	Moderate Buy

Breaking News: Tesla headed to $500… (Ad)

That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla.

So to claim your free digital copy today, simply follow this link and enter your email address.

TMDX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

TMDX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

TransMedics Group Stock vs. The Competition

Type	TransMedics Group	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.80	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	65.43% Upside	27,212.41% Upside	8.86% Upside
News Sentiment Rating	Positive News See Recent TMDX News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/20/2024	Piper Sandler 2 of 5 stars		Lower Target	Overweight ➝ Overweight	$180.00 ➝ $110.00	+41.79%
11/20/2024	Canaccord Genuity Group 1 of 5 stars		Lower Target	Buy ➝ Buy	$109.00 ➝ $104.00	+26.06%
11/18/2024	TD Cowen 4 of 5 stars		Lower Target	Buy ➝ Buy	$175.00 ➝ $120.00	+48.64%
10/29/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$173.00 ➝ $116.00	+30.34%
10/29/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$200.00 ➝ $150.00	+18.82%
10/29/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$200.00 ➝ $125.00	-0.98%
I've got news for you… (Ad) Today, I’m doing something I thought I’d never do… Especially since I’m not normally a “swing for the fences” type of trader. But I’ve been quietly testing a new type of trade for a while now… And the returns are too good not to share with you. Take a look… I can’t guarantee results or against losses, but if you want to discover how I’ll target the triple return before the end of the week watch this FREE briefing with me and expert trader Graham Lindman
10/29/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Matson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$208.00 ➝ $109.00	-13.66%
9/24/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Rescott Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/2/2024	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	G. Sellers Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$151.00 ➝ $178.00	+18.98%
7/15/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$104.00 ➝ $145.00	+0.58%
6/6/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$161.00	+21.03%
7/19/2023	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Daniels Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
2/23/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$70.00 ➝ $75.00	+16.21%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 12:49 PM ET.

TMDX Forecast - Frequently Asked Questions

: According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for TransMedics Group is $131.80, with a high forecast of $178.00 and a low forecast of $104.00.
: 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TransMedics Group in the last year. There is currently 1 hold rating, 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" TMDX shares.
: According to analysts, TransMedics Group's stock has a predicted upside of 64.52% based on their 12-month stock forecasts.
: Over the previous 90 days, TransMedics Group's stock had 1 upgrade by analysts.
: TransMedics Group has been rated by research analysts at Baird R W, Canaccord Genuity Group, JPMorgan Chase & Co., Needham & Company LLC, Oppenheimer, Piper Sandler, Robert W. Baird, and TD Cowen in the past 90 days.
: Analysts like TransMedics Group more than other "medical" companies. The consensus rating for TransMedics Group is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how TMDX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Man behind OpenAI makes shocking new bet (Ad)

Billionaire Sam Altman has become one of the most powerful men in the world by running OpenAI… But there’s a far lesser known investment he’s making that could put OpenAI to shame. In fact this Sam Altman-backed company could actually become a crucial partner for OpenAI… And the US Military… not to mention hundreds of other giant companies around the globe. To make the story even crazier… this company only recently became viable, thanks to an obscure piece of legislation that President Trump signed before he left office… Which ordered the government to take this incredible new technology seriously.

Check out our report right here.

This page (NASDAQ:TMDX) was last updated on 11/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TransMedics Group (TMDX) Stock Forecast & Price Target